GCI Members Dr. Farhia Kabeer and Dr. Yvette Drew publish new findings in Gynecologic Oncology Reports, showing that BRCA1/2 mutations or high HRDetect scores alone may be insufficient to predict PARPi sensitivity in rare gynecological cancers.
Highlights
- A rare case of metastatic gastric-type mucinous endometrial adenocarcinoma (MCG), a newly recognized WHO entity (∼30 cases reported worldwide).
- BRCA1/2 mutations or high HRDetect scores alone may be insufficient to predict PARPi sensitivity in rare, gynecological cancers.
- Molecular classification revealed a pathogenic germline BRCA1 mutation with tumor loss-of-heterozygosity (LOH) and a high HRDetect score (0.96).
- Conversely, the standard HRD score (35) fell below the clinical threshold (≥ 42), and copy number signature analysis classified it as a non-HRD signature (VS4).
- Retrospective patient-derived xenograft (PDX) modeling in mice successfully mirrored the patient’s clinical outcome.
Stay in the loop with the Gynecologic Cancer Initiative: